<div id="readability-page-1"><div>CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Picard Medical Inc. (NASDAQ: PMI) The lead plaintiff deadline throughout the release dated February 3, 2026, should read April 13, 2026 (instead of April 3, 2026). The updated release reads: SCOTT+SCOTT ATTORNEYS AT LAW LLP FILES SECURITIES CLASS ACTION AGAINST PICARD MEDICAL INC. (NASDAQ: PMI) Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Picard Medical Inc., Patrick NJ Schnegelsberg, Matt Schuster, Yuncai “Richard” Fang, Chris Hsieh, Westpark Capital, Inc., Sentinel Brokers Company, Inc., R.F. Lafferty &amp; Co. Inc., American Trust Investments, and MaloneBailey, LLP (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Northern District of California and captioned Louie v. Picard Medical, Inc. et al.,Case No. 5:26-cv-01024, asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased Picard Medical Securities (“PMI”) between September 2, 2025, and October 31, 2025, inclusive (the “Class Period”), and who were damaged thereby. The lead plaintiff deadline in this action is April 13, 2026. LEAD PLAINTIFF DEADLINE ON APRIL 13, 2026 Picard Medical claims to engage in designing, manufacturing, production, supply, marketing, and sale of medical device products. Their website details their most significant product is an artificial heart called “SynCardia TAH.” The company is headquartered in Tucson, Arizona, with operations in the United States, Europe, and China. The complaint alleges that Defendants violated provisions of the Securities Act by making materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and the true nature of the trading activity in its securities. The complaint alleges that Defendants were uniquely situated to orchestrate a pump-and-dump scheme on its class A ordinary shares. After plaintiffs and class members purchased PMI, the complaint alleges that Picard’s stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Picard in online forums, chat groups, and through social media posts with sensational but baseless claims to create a buying frenzy among retail investors. LEAD PLAINTIFF DEADLINE ON APRIL 13, 2026 If you purchased Picard Medical Securities between September 2, 2025, and October 31, 2025, inclusive, and have suffered significant losses, realized or unrealized, you are encouraged to contact Scott+Scott attorney Mollie Chadwick at (619) 233-4565, or via email at mchadwick@scott-scott.com, for more information. The lead plaintiff deadline in this action is April 13, 2026. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed class. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiffs’ counsel, Mollie Chadwick at (619) 233-4565, or via email at mchadwick@scott-scott.com. About Scott+Scott Attorneys at Law LLP Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoing, including securities law and shareholder violations. With 150 attorneys plus supporting staff in eight offices in the United States as well as one office in Canada and three in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our attorneys have been recognized across legal publications, including by Lawdragon for being among the 500 Top Financial Lawyers and the 500 Leading Global Antitrust &amp; Competition Lawyers. In addition, we have received top rankings by WWL: Commercial Litigation, Legal 500 in Antitrust as well as Securities Litigation, Chambers, and Best Lawyers®. Our attorneys have been repeatedly recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit www.scott-scott.com. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAyMDMxNTgxODdyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAyMDMxNTgxODdyMg"/> Mollie Chadwick Scott+Scott Attorneys at Law LLP 600 W. Broadway, Suite 3300, San Diego, CA 92101 (619) 233-4565 mchadwick@scott-scott.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260203158187/en/</div></div>

美国医药设备 ETF - iShares

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

标普健康医疗设备 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

Scott+Scott 律师事务所 LLP 已在加利福尼亚北区美国地方法院对 Picard Medical Inc.（纳斯达克：PMI）提起证券集体诉讼。诉讼指控被告作出了重大虚假陈述，并未披露有关公司运营的不利事实，导致在 2025 年 9 月 2 日至 2025 年 10 月 31 日期间购买 PMI 证券的投资者遭受重大损失。主要原告的截止日期定为 2026 年 4 月 13 日。感兴趣的各方可以联系律师 Mollie Chadwick 获取更多信息

CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Picard Medical Inc. (NASDAQ: PMI)

MorningStar

Picard Medical

更正并替换 Scott+Scott 律师事务所对 Picard Medical Inc.（NASDAQ: PMI）提起的证券集体诉讼